RET C634R is the most common MEN2A germline variant. In advanced / metastatic MEN2A-drive...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-RET-C634R-MTC |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-MTC |
| Sources | SRC-CIVIC SRC-NCCN-CNS-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-RET |
|---|---|
| Variante | C634R (germine — MEN2A) |
| Maladie | DIS-MTC |
| Niveau ESCAT | IB |
| Combinaisons recommandées | selpercatinib en monothérapie, pralsetinib |
| Contre-indiqué en monothérapie | cabozantinib / vandetanib (selective-TKI preferred in selective-TKI era) |
| Résumé des faits | RET C634R is the most common MEN2A germline variant. In advanced / metastatic MEN2A-driven MTC, selpercatinib and pralsetinib have activity comparable to M918T disease (LIBRETTO-001 RET-mutant MTC cohort). FDA labels for selpercatinib/pralsetinib in RET-mutant MTC encompass germline / extracellular-domain variants. C634R also drives prophylactic-thyroidectomy timing in MEN2A kindred. |
Notes
ESCAT IB (slightly lower than M918T because LIBRETTO-531 1L superiority data are most robust in M918T-enriched cohorts; C634 is treated identically by FDA label and clinical practice). OncoKB Level 1. Mandatory pheochromocytoma + hyperparathyroidism screening (MEN2A syndrome). Source-gap: SRC-NCCN-THYROID-2025 placeholder; SRC-LIBRETTO001-DRILON-2020 not yet ingested.
Utilisé par
No reverse references found in the YAML corpus.